CSI Market
Sign In | Register

Keenova Therapeutics Plc (MNK) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access MNK Annual Balance Sheets →
Balance sheet performance over multiple periods helps investors evaluate the financial resilience of Keenova Therapeutics Plc.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2026)
(Dec 31 2025) (Sep 26 2025) (Mar 28 2025) (Sep 27 2024)
Assets
Cash & cash equivalent824.90
Cash & Short-term Investments824.00
Accounts receivable353.10
Inventories487.30
Disposal Group, Including Discontinued Operation, Assets, Current AS0.00
Other Current Assets0.00
Prepaid Expense And Other Assets Current253.40
Total Current Assets1,918.70
Equipment/Property/Plant Net187.20
Goodwill net24.90
Intangible Assets2,174.20
Discontinued operations, Noncurrent0.00
Other Assets, Noncurrent1,169.80
Total Assets5,474.80
Liabilities
Accounts Payable, Current AC89.00
Accrued Liabilities, Current61.70
Long-term Debt and Capital Lease Obligations, Current DE15.00
Other Liabilities, Current472.60
Disposal Group, Including Discontinued Operation, Liabilities, Current LI0.00
Total Current Liabilities638.30
Long-term debt2,525.40
Total Long-term Debt2,525.40
Pension and Other Postretirement Defined Benefit Plans, Liabilities, Noncurrent PE0.00
Accrued Income Taxes, Noncurrent AC119.10
Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent LI0.00
Other liabilities, Noncurrent333.60
Accrued Rebates33.70
Total Liabilities3,516.40
Stockholders' Equity
Common Stock Value0.00
Treasury Stock Value0.00
Additional Paid In Capital Common Stock2,124.70
Retained Earnings / Accumulated Deficit-165.20
Other Equity-1.10
Common Stockholder's Equity1,958.40
Preferred Stockholder's Equity0.00
Total Stockholder's Equity1,958.40
Liabilities & Stockholder's Equity5,474.80
4 historic quarters locked

Sign in to unlock the full Keenova Therapeutics Plc balance sheet history.

Sign In Create Free Account

About Keenova Therapeutics Plc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 11, 2026
  • Source: mnk-20260630.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001628280-26-055614

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.